Results 1 to 10 of about 64,020 (238)

Inhibin alpha-subunit (INHA) expression in adrenocortical cancer is linked to genetic and epigenetic INHA promoter variation. [PDF]

PLoS ONE, 2014
Adrenocortical carcinoma (ACC) is a rare, but highly malignant tumor of unknown origin. Inhibin α-subunit (Inha) knockout mice develop ACCs following gonadectomy.
Johannes Hofland, Jacobie Steenbergen, Jacoba M Voorsluijs, Michael M P J Verbiest, Ronald R de Krijger, Leo J Hofland, Wouter W de Herder, Andre G Uitterlinden, Richard A Feelders, Frank H de Jong   +9 more
doaj   +10 more sources

Association between INHA gene polymorphisms and litter size in Hainan black goats [PDF]

PeerJ, 2023
Background The inhibin alpha (INHA) gene is one of the important genes affecting the reproductive traits of animals. Hainan black goats are the main goat breed in Hainan Island (China), whose development is limited by low reproductive performance ...
Zhengyu Bian, Kunpeng Li, Si Chen, Churiga Man, Fengyang Wang, Lianbin Li   +5 more
doaj   +3 more sources

INHA acts as a novel and potential biomarker in lung adenocarcinoma and shapes the immune-suppressive tumor microenvironment

Translational Oncology, 2023
Background: INHA expression has been correlated with the development, growth, and progression of multiple cancer types. However, the biological role of INHA has not been investigated in patients with lung adenocarcinoma (LUAD).
Xun Zhang, Xinyu Zhang, Dizhi Jiang, Wendi Zheng, Huimin Wang, Yu Tian, Bo Cheng   +6 more
doaj   +2 more sources

Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme

Journal of Enzyme Inhibition and Medicinal Chemistry, 2021
A series of 1,2,3-trisubstituted indolizines (2a–2f, 3a–3d, and 4a–4c) were screened for in vitro whole-cell anti-tubercular activity against the susceptible H37Rv and multidrug-resistant (MDR) Mycobacterium tuberculosis (MTB) strains.
Katharigatta N. Venugopala, Sandeep Chandrashekharappa, Pran Kishore Deb, Christophe Tratrat, Melendhran Pillay, Deepak Chopra, Nizar A. Al-Shar’i, Wafa Hourani, Lina A. Dahabiyeh, Pobitra Borah, Rahul D. Nagdeve, Susanta K. Nayak, Basavaraj Padmashali, Mohamed A. Morsy, Bandar E. Aldhubiab, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha, Michelyne Haroun, Sheena Shashikanth, Viresh Mohanlall, Raghuprasad Mailavaram   +21 more
doaj   +2 more sources

Spinal cord injury–induced overflow incontinence reshapes the activin–follistatin–inhibin axis in mouse bladder and kidney [PDF]

Frontiers in Molecular Biosciences
BackgroundSpinal cord injury is a leading cause of neurogenic bladder and upper urinary tract deterioration, yet the molecular remodeling of epithelial-stromal signaling axes in this context remains incompletely defined.
Yucheng Shen, Yucheng Shen, Shengkai Yang, Shengkai Yang, Hai Zhou, Yongkun Zhu, Zhong Wang, Weimin Jiang   +7 more
doaj   +2 more sources

Identification of Novel Inhibitor of Enoyl-Acyl Carrier Protein Reductase (InhA) Enzyme in Mycobacterium tuberculosis from Plant-Derived Metabolites: An In Silico Study

Antibiotics, 2022
Mycobacterium tuberculosis (M.tb.) enoyl-acyl carrier protein (ACP) reductase (InhA) is validated as a useful target for tuberculosis therapy and is considered an attractive enzyme to drug discovery.
Kratika Singh, Niharika Pandey, Firoz Ahmad, Tarun Kumar Upadhyay, Mohammad Hayatul Islam, Nawaf Alshammari, Mohd Saeed, Lamya Ahmed Al-Keridis, Rolee Sharma   +8 more
doaj   +2 more sources

Prevalence of katG and inhA mutations associated with isoniazid resistance in Mycobacterium tuberculosis clinical isolates in Cameroon

BMC Microbiology
Background The acquisition of isoniazid (INH) resistance is alarming, considering its importance as a key drug that forms the core of multidrug treatment regimens for tuberculosis (TB). Genetic mutations in the katG and inhA promoter regions play crucial
Vanessa Ninkeh Nono, Edouard Akono Nantia, Awelani Mutshembele, Sorelle Nguimfack Teagho, Yannick Willy Kamdem Simo, Brenda Shile Takong, Yvonne Josiane Djieugoue, Yannick Patrick Assolo, Suzanne Magloire Ongboulal, Stanley Nkemnji Awungafac, Sara Eyangoh, Eric Mensah, Ndivhuho Agnes Makhado, Valerie Flore Donkeng Donfack   +13 more
doaj   +2 more sources

InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis.

PLoS ONE, 2020
We previously identified a diazaborine series with potential for development as a new tuberculosis drug. This series has activity in vitro and in vivo and targets cell wall biosynthesis via inhibition of InhA.
Lindsay Flint, Aaron Korkegian, Tanya Parish   +2 more
doaj   +4 more sources

Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.

European journal of medicinal chemistry, 2020
Tuberculosis, caused by Mycobacterium tuberculosis, is a serious infectious disease and remains a global health problem. There is an increasing need for the discovery of novel therapeutic agents for its treatment due to the emerging multi-drug resistance.
Hilal Doğan, Ş. D. Doğan, M. Gündüz, V. Krishna, C. Lherbet, D. Sriram, O. Şahin, E. Sarıpınar   +7 more
semanticscholar   +3 more sources

Computational evaluation of marine demospongiae sponges metabolites activity as mycolic acid biosynthesis inhibitors in Mycobacterium tuberculosis

International Journal of Mycobacteriology, 2023
Background: Mycobacterium tuberculosis is a bacterium that has historically had a substantial impact on human health. Despite advances in understanding and management of tuberculosis (TB), the disease remains a crucial problem that necessitates ongoing ...
Abdullah R Alanzi
doaj   +1 more source